About us
Simris is a biotechnology company committed to transforming cancer treatment through its proprietary pipeline of next-generation ADC payloads. These payloads are born from world-class cyanobacterial science, proprietary conjugation methods, and collaborations with leading research institutions.
We are currently optimising novel Microcystin toxin variants for use in advanced ADCs, targeting both haematologic and solid tumours.
Our research team leverages close to 20 years of cyanobacteria expertise and our exclusive strain library to efficiently develop and scale novel payloads. This unique platform gives Simris a significant competitive edge in the emerging ADC landscape.
We operate a collaboration-first strategy, building value through partnerships with biopharma companies committed to delivering the next leap in targeted cancer therapies.
Simris Group is headquartered in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market (SIMRIS, ISIN: SE0008091664).
Name: Dr Alexis Roberts-McIntosh
Title: Chief Executive Officer since March 2024
Born: 1962
Alexis holds a PhD in Medicinal Chemistry, with an early career in GSK and has spent the last 27 years transitioning upwards through ever-more senior appointments at some of the world's global pharmaceutical companies including Pfizer, Johnson and Johnson and Abbott. Driving innovative healthcare products to commercialisation, managed complex teamsand large global P&Ls.
Non-Executive Director, Aureum DX Ltd.
Holdings: 0 B-shares
Name: Christoffer Tell
Title: Chief Financial Officer since Feb 2021
Born: 1987
Christoffer has over 10 years of experience in leading roles across different industry sectors. Previous to Simris Christoffer held the position of CFO för Global Gaming and CFO för Examec Group. Today he works as an independent consultant and auditor.
Christoffer Tell AB - Board member.
CORMKA AB – Chairman.
Mainstream Media Scandinavia AB - Chairman, CEO.
Simrishamns Låsservice AB - Board deputy.
Newbury Pharmaceuticals AB - CFO.
Holdings: 800 000 B-shares, 430 000 warrants.
Name: Dr Heike Enke
Title: CSO non-ADC Technologies at Simris Biologics
Born: 1975
Heike holds a PhD in Genetic Biology from Humboldt University in Berlin and is a co-founder of the company Cyano Biotech GmbH, acquired by Simris in August 2022. She has more than 20 years of experience in cyanobacterial strain development during which time she has built a collection of almost 1,200 strains of cyanobacteria. Heike has performed extensive R&D optimising cyanobacteria for biofuel production and to identify novel, natural compounds for use in pharmaceuticals, cosmetics and agricultural products. She is also a co-inventor of Simris’ platform for the development of ADC-payloads from cyanobacterial toxins.
Heike currently coordinates all Research & Development activities outside of Simris’ ADC-technology. In this capacity she leads cyanobacterial strain development activities and is tasked with the identification of new opportunities within the cyanobacteria/ microalgae space. This includes the research collaboration with Malmö University which evaluates compounds and extracts from cyanobacteria and microalgae for use within the cosmetic industry. Heike is also responsible for the development and production of the cyanobacterial standards that Simris Biologics supplies to water authorities tasked with monitoring the presence of cyanobacterial toxins in public water bodies.
None.
Holdings: 3 932 246 B-shares including closely related parties.